ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1701

High TNFAIP3-Transfected Cell Activity: An In Vitro Model for Phagocyte Study of Monogenic Behçet’s Disease Pathophysiology

Patricia Pontes Aires1, André Cunha1, DANIELA GERENT PETRY PIOTTO1, Maria Teresa Terreri2 and Sandro Perazzio1, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2Universidad Federal São Paulo, São Paulo, Brazil

Meeting: ACR Convergence 2022

Keywords: Autoinflammatory diseases, Behçet's Syndrome, immunology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Innate Immunity Poster: Basic and Translational Science

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: A20 haploinsufficiency (A20HA), an important monogenic etiology of Behçet’s disease (BD), is caused by loss-of-function mutations in TNFAIP3. Although monocytes play an important role on BD pathophysiology, the effect of TNFAIP3 mutations in these cells needs further elucidation. Our group previously described high soluble CD40 ligand (sCD40L) serum levels, which induced phagocyte hyperactivity. This study aimed to assess different phagocyte function of THP-1 (monocytic) cells transfected with the pathogenic TNFAIP3 variant L227X.

Methods: THP-1 or HL-60 (neutrophilic) cells were transfected with a GFP-tagged plasmid containing either TNFAIP3 or mutated TNFAIP3-L227X gene. Flow cytometry analysis before and after stimulus with sCD40L, monosodium urate crystals (MSU) or phorbol-miristate-acetate (PMA): 1) phagocytic activity was assessed using fluorescent zymosan particles; 2) CellRox Deep Red assessed reactive oxygen species (ROS) production; 3) Ki-67 expression quantified cell proliferation.

Results: THP-1-TNFAIP3-L227X [mean of fluorescence intensity (MFI) 94748±28804] showed higher phagocytic activity than THP-1 (34039.33±4945; p< 0.001) and THP-1-TNFAIP3 (18476±379; p< 0.001) at baseline and after sCD40L stimulus (respectively, 76265±15858 vs 35835±1133 vs 25379±3472; p< 0.05; Figure 1). Similarly, HL-60-TNFAIP3-L227X cells (17480±2306) showed higher phagocytic activity than HL-60 (5862±410; p< 0.01) at baseline and after MSU stimulus (16869±3496 vs 5482±324; p< 0.01). Conversely, percentage of phagocytosing THP-1-TNFAIP3-L227X cells (13.3%±2.6%) was lower than THP-1-TNFAIP3 (23.7±2.5%, p< 0.01); on the other hand, there was no statistical difference in the percentage of HL-60-TNFAIP3-L227X phagocytosing cells, compared to HL-60-TNFAIP3. Constitutional ROS production by THP-1-TNFAIP3 cells (MFI=291919±27871) was higher than THP-1 (98226±7285; p< 0.001) and maintained after PMA (561333±84760 vs 399628±69821; p< 0.001; Figure 2). ROS production by THP-1-TNFAIP3 was also higher than THP-1-TNFAIP3-L227X (230711+7895, p< 0.001). Despite THP-1 typical arrest in G2 phase, PMA-induced Ki-67 expression of THP-1-TNFAIP3-L227X was significantly increased (19184±8934) compared with THP-1 (2434±353) and THP-1-TNFAIP3 (4463±357; p< 0.01; Figure 3).

Conclusion: THP-1-TNFAIP3-L227X presented higher phagocytic activity, a pattern also observed by neutrophilic cells (HL-60-TNFAIP3-L227X), suggesting a specific mutation-induced phenotype. Paradoxical higher MFI of THP-1-TNFAIP3-L227X with lower percentage cell number could be explained by phagocytosis of multiple zymosan particles by a single cell. Decreased THP-1-TNFAIP3-L227X oxidative burst suggests a state of cell exhaustion. Higher PMA-induced THP-1TNFAIP3-L227X proliferation could eventually be explored by functional studies monogenic BD patients. THP-1-TNFAIP3 proliferation rates were low and unchanged upon stimulation, reinforcing the role of A20 as an NF-κB pathway inhibitor.

Supporting image 1

Figure 1: phagocytosis of Alexa-Fluor 594-tagged zymosan particles by THP_1 cells. Comparison of THP_1, THP_1-TNFAIP3-WT and THP_1-TNFAIP3-L227X cells, in triplicate, using two-way ANOVA. Results indicate higher phagocytic rates for THP_1-TNFAIP3-L227X at baseline and upon stimulation with sCD40L * p < 0.05; ** p < 0.01; *** p < 0.001

Supporting image 2

Figure 2: production of ROS by THP_1 cells, before and after PMA stimulus. Comparison of THP_1, THP_1-TNFAIP3-WT and THP_1-TNFAIP3-L227X cells, in triplicate, using two-way ANOVA. Results indicate higher oxidative burst in THP_1-TNFAIP3-WT cells and unresponsiveness of THP_1-TNFAIP3-L227X, which could indicate a state of cell exhaustion. * p < 0.05; *** p < 0.001

Supporting image 3

Figure 3: analysis of THP_1 cell proliferation using flow cytometry, through Ki-67 staining, before and after an 18-hour incubation with PMA. Comparison of THP_1, THP_1-TNFAIP3-WT and THP_1-TNFAIP3-L227X cells, in triplicate, using two-way ANOVA. Results show higher proliferation rates for THP_1-TNFAIP3-L227X and low proliferation rates for THP_1-TNFAIP3-WT. * p < 0.05; ** p < 0.01; *** p < 0.001


Disclosures: P. Pontes Aires, None; A. Cunha, None; D. PIOTTO, None; M. Terreri, Roche, Pfizer, UCB, Janssen, Bristol-Myers Squibb(BMS), Eli Lilly, AbbVie/Abbott; S. Perazzio, None.

To cite this abstract in AMA style:

Pontes Aires P, Cunha A, PIOTTO D, Terreri M, Perazzio S. High TNFAIP3-Transfected Cell Activity: An In Vitro Model for Phagocyte Study of Monogenic Behçet’s Disease Pathophysiology [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/high-tnfaip3-transfected-cell-activity-an-in-vitro-model-for-phagocyte-study-of-monogenic-behcets-disease-pathophysiology/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-tnfaip3-transfected-cell-activity-an-in-vitro-model-for-phagocyte-study-of-monogenic-behcets-disease-pathophysiology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology